On the Horizon: A Brief Look at Potential Analgesics of the Future
At PAINWeek 2018 in Las Vegas, Jeff Gudin, MD, director of pain management and palliative care at Englewood Hospital and Medical Center, in New Jersey, and Co-Editor-At-Large of PPM, shared insight into novel analgesics that are either proving intriguing and successful in research or emerging into the marketplace. Among the noteworthy products and targets:
Opioid Products
- Abuse-deterrent formulations
- Slow-entry formulations
- Partial agonists
- Opioid-like molecules
- Biased opioid ligands
- Kappa opioid receptor agonists
- Prodrugs
Non-Opioid Products
- Alpha2 adrenergic agonists
- NMDA receptor agonists
- Gabapentinoids
- Novel NSAIDS
- Nerve growth factor (NGF) antagonists (read more)
- Glial cell modulators
- Cannabinoids
- Topicals, specifically new formulations and technologies that offer improved delivery
Watch for PPM in-depth coverage on each of these novel analgesics in the coming months.